David A. Siegel Xeris Biopharma Holdings, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 893,242 shares of XERS stock, worth $6.48 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
893,242
Previous 1,056,779
15.48%
Holding current value
$6.48 Million
Previous $4.94 Million
46.61%
% of portfolio
0.02%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding XERS
# of Institutions
236Shares Held
94.1MCall Options Held
251KPut Options Held
61.8K-
Black Rock Inc. New York, NY10.3MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.83MShares$71.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.84MShares$42.3 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.14MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $986M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...